顺铂联合白细胞介素-2治疗恶性胸腔积液的研究

目的观察胸腔内注入顺铂与白细胞介素-2治疗恶性胸腔积液的有效性和安全性。方法60例恶性胸腔积液患者的治疗用顺铂联合白细胞介素-2(A组)23例，单用顺铂(B组)19例, 单用白细胞介素-2(C组)18例。用一次性中心静脉导管行胸腔置管和闭式引流胸腔积液，A组注入顺铂40～60 mg+白细胞介素-2 100万u，B组注入顺铂60 mg，C组注入白细胞介素-2 100万u，1次／周，连续注射2～3周，4周后观察两组的疗效及不良反应。结果A、B、C三组总有效率分别82.6％、68.4％、66.7％；生活质量提高，KPS评分改善率为82.6％ 、78.9％、77.8％ ；三组不良反应无显著差异。结论胸腔闭式引流后灌注顺铂联合白细胞介素-2治疗恶性胸腔积液的疗效优于单用顺铂及单用白细胞介素-2，且不良反应轻。

Cisplatin Combined with Interleukin-2 to Treat Malignant Pleural Effusion

ObjectiveTo evaluate the efficacy and safety of cisplatin（PPD） plus interleukin-2（IL-2） to therapy malignant pleural effusion．MethodsSixty patients with malignant pleural effusion were divided into three groups：A group (n=23) injected by 40~60 mg of PPD and 1 000 000 units of IL-2，B group (n=19) injected with 60 mg PPD,C group (n=18) injected with 1 000 000 units of IL-2．The doses were given one time every week, for 2～ 3 weeks．The therapeutic effect and adverse reactions were observed after four weeks．ResultsThe total effective rates in the treatment group A,B and C were respectively 82.6％,68.4％ and 66.7％ respectively，and quality of life and KPS score improvement rate was 82.6%, 78.9%and 77.8%. Side effects were no significant difference among 3 groups. ConclusionPPD combined with IL-1 was efficacy and safety in the treatment of patients with malignant pleural effusions．